Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
One-third of asylum applications by Iranians approved in Germany - 2Irish defence minister's trip to Lebanon cancelled
- 3PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- 4This Unique National Park In Canada Is Famous For Its Otherworldly Limestone Monoliths
- 56 Shades Brands For Seniors
- 5 Side interests That Work on Psychological wellness
- Mexico says a third of 130,000 missing people might be alive, fueling criticisms by families
- Step by step instructions to Open a Lovely Waterway Voyage Insight: Conveniences, Administrations, and Elite Offers
- This Is Canada's Only Province Without Any Bears
- 6 Famous Urban communities for Shopping on the planet
- Early diagnosis leads King Charles to scale back cancer treatment in the new year
- 6 Famous Urban communities for Shopping on the planet
- Share your number one city visit transport that leaves a mark on the world wake up!
- The pace of hiring just fell to the lowest since 2011, outside of the pandemic
